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Abstract  20	  
The spread of cancer cells to distant organs represents a major clinical challenge in the treatment of 21	  
cancer. Epithelial-mesenchymal transition (EMT) has emerged as a key regulator of metastasis in 22	  
some cancers by conferring an invasive phenotype. As well as facilitating metastasis, EMT is 23	  
thought to generate cancer stem cells and contribute to therapy resistance. The EMT pathway is 24	  
therefore of great therapeutic interest in the treatment of cancer and could potentially be targeted 25	  
either to prevent tumor dissemination in patients at high risk of developing metastatic lesions or to 26	  
eradicate existing metastatic cancer cells in patients with more advanced disease. This review 27	  
discusses approaches for the design of EMT-based therapies in cancer, summarizes evidence for 28	  
some of the proposed EMT targets and reviews the potential advantages and pitfalls of each 29	  
approach. 30	  
 31	  
Targeting EMT in cancer 32	  
Epithelial-mesenchymal transition (EMT) describes the process whereby cells shed their epithelial 33	  
properties and adopt a more mesenchymal and invasive phenotype [1, 2]. EMT is characterized by 34	  
the loss of cell-cell adhesions and apicobasal polarity, and the transition to a cell type with a more 35	  
spindle-like morphology that is capable of invading the extracellular matrix [1, 2]. Molecularly, 36	  
EMT involves the downregulation of epithelial-type proteins (e.g., the adherens junction protein E-37	  
cadherin and cytokeratin intermediate filament proteins), and the acquisition of mesenchymal 38	  
markers including EMT-associated transcription factors and the intermediate filament protein 39	  
vimentin (Box 1) [1, 2]. This phenomenon was first described in the context of embryonic 40	  
development [3], in which primary EMT events play an integral role in processes such as 41	  
gastrulation and neural crest formation. In the adult, EMT is implicated in wound healing, 42	  
placentation, tissue fibrosis and cancer metastasis [4].  43	  
 44	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Metastasis is the major cause of death in cancer patients. The transition of cancer cells from a 45	  
highly proliferative, relatively immobile epithelial phenotype to a more invasive cell type via EMT 46	  
is increasingly accepted as having an instrumental role in tumor metastasis [5]. Given the incidence 47	  
of metastasis and its impact on patient prognosis, new therapeutic strategies are required to prevent 48	  
the dissemination of organ-confined cancers in patients at high risk of developing metastases and/or 49	  
to eliminate existing metastatic cells in patients with more advanced disease. The pharmacological 50	  
targeting of EMT in specific cancer types may represent such a strategy.  51	  
 52	  
Studies investigating EMT-like features in clinical cancer samples and in vivo models of EMT are 53	  
now emerging [6-11], allaying some initial skepticism regarding the actual role for EMT in cancer 54	  
metastasis and the ability to translate in vitro data to the clinical setting [12]. Some of the most 55	  
prominent studies investigating the in vivo relevance of EMT have been performed in models of 56	  
breast cancer. For example, Bonnomet et al. [6] developed an in vivo model of mammary EMT by 57	  
injecting severe combined immunodeficiency (SCID) mice with vimentin-negative MDA-MB-468 58	  
breast cancer cells. These mice develop primary tumors that display heterogeneous regions of 59	  
vimentin positivity and analysis of these vimentin-positive cell populations show enrichment for 60	  
other mesenchymal genes. In addition, circulating tumor cells were also found to be enriched with 61	  
EMT markers [6], indicating that spontaneous EMT events may facilitate intravasation and 62	  
metastatic dissemination of breast cancer cells in vivo. EMT is also a feature of myc-initiated breast 63	  
cancer in mice [7]. Furthermore, studies using clinical breast cancer samples have demonstrated that 64	  
the basal-like and claudin low molecular breast cancer subtypes, which are prone to metastasize, are 65	  
transcriptionally akin to mesenchymal cells [8, 13], providing compelling evidence for a role for 66	  
EMT in human cancers.  67	  
 68	  
As well as facilitating the metastatic dissemination of cancer cells, EMT is associated with therapy 69	  
resistance in some cancers [14, 15]. EMT markers are enriched in pancreatic cancer cell lines that 70	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are resistant to gemcitabine, 5-fluorouracil and cisplatin [16]; chemoresistance to 5-fluorouracil 71	  
correlates with the expression of mesenchymal markers in breast cancer cells [17]; and non-small 72	  
cell lung carcinoma cells induced to undergo EMT with either epidermal growth factor (EGF) or 73	  
transforming growth factor β (TGFβ) show enhanced resistance to cisplatin and paclitaxel [14]. 74	  
EMT is also associated with resistance to tyrosine kinase inhibitors in hepatocellular and non-small 75	  
cell lung carcinomas [18, 19], and resistance to hormonal therapy in breast cancers [20].  76	  
 77	  
In light of the growing body of evidence implicating EMT as a clinically-relevant mechanism for 78	  
targeting tumor metastasis and the observation that cancer cells surviving treatment are enriched in 79	  
EMT markers, the need to develop new pharmacological therapies to target this process in cancer is 80	  
apparent. However, key questions remain regarding the practicality of targeting EMT to prevent or 81	  
reduce metastasis. This review will discuss targeting EMT as potential adjuvant therapy in the 82	  
treatment of cancer. 83	  
 84	  
Strategies for targeting the EMT pathway to control cancer metastasis 85	  
There are at least four stages to pharmacologically target EMT events in cancer. These are depicted 86	  
in Figure 1 and involve inhibiting EMT induction (either via the antagonism of extracellular EMT-87	  
inducing stimuli or the inhibition of critical EMT-associated signal transduction pathways), 88	  
targeting the mesenchymal cell or inhibiting mesenchymal-epithelial transition (MET). These broad 89	  
strategies for targeting the EMT pathway to control cancer metastasis are discussed in detail below. 90	  
Despite evidence for the potential effectiveness of each of these approaches, all have possible 91	  
limitations; in all cases the pharmacological targets so far identified go beyond the markers 92	  
classically associated with EMT [4]. Table 1 summarizes proposed EMT targets that belong to the 93	  
top three classes of drug targets (i.e. receptors, enzymes and transporter proteins [21]). This list is 94	  
very different to the traditional mesenchymal markers (shown in Box 1), which feature many 95	  
structural proteins and transcription factors. 96	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 97	  
Strategies to inhibit EMT induction 98	  
Novel therapies for inhibiting EMT induction may benefit cancer patients at high risk of developing 99	  
metastasis, and would be intended to stop locally-confined, pre-metastatic cancers from undergoing 100	  
EMT. Such approaches may include agents to block EMT-inducing signals from the tumor 101	  
microenvironment or to inhibit critical downstream signal transduction pathways (Figure 1). The 102	  
use of preemptive therapies to inhibit metastasis in early-stage cancers may be controversial and 103	  
would depend on the safety and tolerability profile of such agents, and could also present significant 104	  
challenges to clinical trial design [22]. However, given the link between EMT, cancer stem cells 105	  
and therapy resistance [14, 16-19, 23], strategies to block EMT induction as early adjuvant therapy 106	  
may also increase the susceptibility of cancer cells to conventional chemotherapeutics, shortening 107	  
the overall duration of therapy and likelihood of relapse in these patients.  108	  
 109	  
Many signals from the tumor microenvironment can induce EMT in cancer cells. These signals 110	  
include reduced oxygen tension, cytokines and growth factors [24-27]. The therapeutic targeting of 111	  
specific cell surface receptors that are activated by these extracellular signals may be one strategy to 112	  
prevent EMT in cancer cells. For example, in vitro studies show that the epidermal growth factor 113	  
(EGF) receptor kinase inhibitor AG1478 blocks EGF-induced EMT in human breast cancer cells 114	  
[27], and inhibition of the TGFβ receptor kinase using SB431542 blocks transforming growth factor 115	  
β (TGFβ)-induced EMT in pancreatic cancer cells [28]. However, one caveat of this approach, 116	  
which may limit the clinical utility of these agents, is the diversity of signals capable of inducing 117	  
EMT that may be present in the tumor microenvironment. Resistance to these therapies may rapidly 118	  
emerge if other EMT-inducing pathways remain intact, as has been observed in lung carcinoma 119	  
studies [15]. 120	  
 121	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Limitations related to the redundancy of EMT-inducing stimuli in the tumor microenvironment may 122	  
be overcome by targeting mutual intracellular signal transduction pathways. Pharmacological 123	  
targeting of crucial signal transduction pathways represents a second approach to inhibit the 124	  
induction of EMT. One example is signal transducer and activator of transcription 3 the 125	  
transcription factor STAT3, which has critical roles in EMT in a range of human cancers [29-31]. 126	  
Interleukin-6 (IL-6)-induced EMT in CAL27 head and neck squamous carcinoma cells is dependent 127	  
on STAT3 signaling [26], and STAT3 is required for EGF-induced EMT in MDA-MB-468 breast 128	  
cancer cells [27] and OVCA 433 ovarian cancer cells [32]. Although transcription factors have 129	  
traditionally been viewed as unfavorable for therapeutic targeting [33], several small molecule 130	  
inhibitors of transcription factors have now been developed, including the STAT3 inhibitors Stattic 131	  
[33] and S3I-201 [34]. Therefore, the development of novel inhibitors for other transcription factors 132	  
(e.g., Snail, Slug, Zeb and Twist) may be a potential strategy for pharmacologically inhibiting EMT 133	  
induction in human cancers. Early evidence for the effectiveness of inhibiting EMT-associated 134	  
transcription factors to block EMT induction in other cell types has been shown in retinal pigment 135	  
epithelial cells, where silencing of Snail attenuates EMT induction by TGFβ [35].  136	  
 137	  
An alternative to targeting EMT-associated transcription factors to inhibit the induction of EMT 138	  
could be the specific targeting of other signal transducers upstream of transcriptional regulation. 139	  
Such an upstream event may include calcium signaling, given that the intracellular calcium signal 140	  
regulates EMT induced by either EGF or hypoxia in MDA-MB-468 breast cancer cells [29]. The 141	  
transient receptor potential melastatin 7 (TRPM7) channel, a plasma membrane ion channel with an 142	  
integral alpha kinase domain, may be a potential drug target in calcium-dependent STAT3 143	  
activation and EMT-induction in breast cancer [29]. 144	  
 145	  
One of the potential limitations of targeting EMT induction in cancer is the presence of metastases 146	  
at the time of diagnosis. Although inhibitors of EMT induction may be highly effective as adjuvant 147	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therapy to prevent early metastasis or drug resistance, patients with pre-existing metastases or 148	  
cancer cells that have already undergone this transition, may receive little/no benefit from inhibitors 149	  
of EMT induction. Indeed, the emerging requirement for the reverse transition (MET) for effective 150	  
metastasis, as discussed below, suggests that agents that target cells in the mesenchymal state could 151	  
possibly be contraindicated in late stage disease [36]. 152	  
 153	  
Targeting the mesenchymal phenotype 154	  
As discussed above, EMT is characterized by the acquisition of a suite of mesenchymal cell 155	  
markers (Box 1). These markers, which include vimentin, N-cadherin and fibronectin, are 156	  
associated with increased cell invasion, and are frequently expressed in circulating tumor cells and 157	  
metastatic lesions [10, 37, 38]. Targeting these mesenchymal proteins may therefore be a 158	  
mechanism to eliminate or paralyze existing metastatic cancer cells in patients with more advanced 159	  
disease (Figure 1). As well as targeting invasive, mesenchymal-type carcinoma cells, agents that 160	  
specifically target mesenchymal markers may also benefit patients with cancers of a mesenchymal 161	  
origin (i.e. sarcomas) [39]. Although many of these markers do not belong to the protein classes 162	  
typically associated with pharmacological modulation [21], some studies have targeted these classic 163	  
mesenchymal proteins to inhibit metastasis and reduce resistance to conventional chemotherapy, 164	  
with some initial success. Withaferin-A is a bioactive compound extracted from Withania somnifera 165	  
that has been shown to promote degradation of the intermediate filament protein vimentin [40]. In 166	  
human breast and lung cancer cell lines Withaferin-A inhibits cell migration and invasion, with 167	  
higher concentrations associated with reduced cell number and apoptosis [40]. Withaferin-A also 168	  
inhibits metastasis formation in vivo. Studies in soft tissue sarcoma cells have shown that 169	  
Withaferin-A induces apoptosis and that malignant cell lines are more sensitive to this agent relative 170	  
to normal vimentin-expressing cell lines, possibly due to higher expression of soluble vimentin 171	  
[41]. Thus, although vimentin has important physiological roles (e.g., smooth muscle force 172	  
development [42]), selective targeting of vimentin-expressing cancer cells may be possible. 173	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Targeting of N-cadherin using a monoclonal antibody approach has also been shown to inhibit 174	  
prostate cancer cell invasion and reduce metastasis formation [43]. 175	  
 176	  
Targeting EMT-associated transcription factors may also affect the mesenchymal cell type. For 177	  
example, inhibition of Twist in a highly metastatic mammary carcinoma cell line reduces the 178	  
frequency of lung metastases in a mouse model of breast cancer [44]. Twist silencing also reduced 179	  
the number of circulating tumor cells in this model without affecting anchorage-independent growth 180	  
and survival, indicating that Twist has critical roles in cancer cell invasion and intravasation [44], 181	  
which may be exploited therapeutically. In addition to the possibility of targeting EMT-associated 182	  
transcription factors, recent progress in the development of microRNA-based therapies may mean 183	  
that targeting of specific microRNAs could be used to inhibit cancer cell invasion via EMT [45]. 184	  
Indeed, AC1MMYR2, a specific small molecule inhibitor of miR-21 production, reduces EMT 185	  
markers and inhibits invasion of glioblastoma, breast cancer and gastric cancer cell lines [46]. 186	  
However, one limitation of targeting the invasive capacity of mesenchymal-type cancer cells may 187	  
be the conversion of cancer cells to an alternative form of cell migration (e.g., amoeboid migration). 188	  
This mesenchymal-amoeboid plasticity may be responsible for the therapeutic failure of protease 189	  
inhibitors in Phase III clinical trials as anti-metastatic agents in breast cancer [47].  190	  
 191	  
Signals from the microenvironment may also be involved in maintaining the mesenchymal 192	  
phenotype. Autocrine signaling via the Axl receptor tyrosine kinase and its ligand Gas6 (growth 193	  
arrest specific 6) is implicated in maintaining the mesenchymal phenotype in MDA-MB-231 breast 194	  
cancer cells, and Axl is up-regulated in MCF10A mammary epithelial cells induced to undergo 195	  
EMT [48]. Axl silencing markedly reduces breast cancer metastasis in mouse models and is 196	  
associated with improved overall survival [48]. Rigel, Inc. has developed a small molecule inhibitor 197	  
of Axl kinase (BGB324, formerly R428) with nanomolar on-target activity and oral bioavailability 198	  
[49]. BGB324 inhibits breast cancer metastasis and synergizes with cisplatin to inhibit liver 199	  
Page 9 
	  
metastases in a mouse model of breast cancer [49]. These studies indicate that inhibition of some 200	  
cell surface receptors may have roles beyond the initiation of EMT and may be used to target the 201	  
mesenchymal cell type at later stages of the metastatic cascade. 202	  
 203	  
The acquisition of stem-like characteristics may make therapeutic targeting of mesenchymal cells 204	  
challenging. Despite this, methods to target the plasticity of these cells have been proposed and 205	  
include the development of monoclonal antibodies directed against cell surface markers of stemness 206	  
(e.g., CD44) [50]. Having identified molecular similarities between breast cancer stem cells and 207	  
EMT, Gupta et al. have used a high-throughput screening approach to identify compounds that may 208	  
selectively target this cell population [51]. Salinomycin, a potassium ionophore, was identified as 209	  
having significant toxicity against mesenchymal-type breast cancer cells (independent of the 210	  
mechanism used to induce EMT in these cells) and reduced the proportion of CD44HIGH/CD24LOW 211	  
breast cancer stem cells existing in heterogeneous cultures of HMLER and SUM159 cell lines [51]. 212	  
This is in contrast to treatment with paclitaxel, which significantly increased the proportion of 213	  
CD44HIGH/CD24LOW cells, consistent with the enrichment for EMT and stem cell markers in breast 214	  
cancer cell lines surviving chemotherapy [51]. Although this study and others investigating 215	  
strategies to target EMT-associated stemness show promising results, additional research is required 216	  
to further establish the in vivo efficacy of these agents, their adjuvant role, possible resistance in this 217	  
plastic cell population and their ability to selectivity target cancer stem cells while preserving rare 218	  
adult stem cell populations. 219	  
 220	  
Targeting mesenchymal-epithelial transition (MET)  221	  
MET is an emerging concept in cancer research that describes the reversion of mesenchymal-like 222	  
cancer cells to a more differentiated, epithelial-like state [11]. This process helps to explain the 223	  
disconnection between the mesenchymal nature of invasive cancer cells and the epithelial nature of 224	  
metastatic lesions.  225	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 226	  
During EMT, cancer cells often relinquish their proliferative program in favor of invasive capacity. 227	  
For example, mesenchymal-type cancer cells at the invasive front of metastatic colorectal 228	  
adenocarcinomas exhibit a loss of the proliferative marker Ki-67 [52], and Snail-transfected Madin-229	  
Darby canine kidney cells show impaired cell cycle progression [53]. Furthermore, an inverse 230	  
relationship between ZEB1-induced EMT and MYB-driven proliferation has recently been 231	  
demonstrated in various human breast cancer systems [54]. MET may therefore be a requisite step 232	  
in the reversion to a cell type more suited for proliferation and colonization of the secondary organ.  233	  
 234	  
MET may be triggered by the withdrawal of EMT-promoting factors from the primary site, signals 235	  
from the secondary microenvironment or a combination of these two processes [11]. Many of the 236	  
strategies discussed above to inhibit the induction or maintenance of EMT by blocking EMT-237	  
promoting signals from the primary microenvironment are effectively associated with 238	  
mesenchymal-epithelial like transitions. While these strategies to promote MET may be highly 239	  
effective in preventing the invasive dissemination of organ-confined cancers, they could also 240	  
conceivably hasten MET-dependent colonization of cancer cells that have already left the primary 241	  
tumor site and/or reinforce the viability of metastatic deposits. Paradoxically, strategies to lock 242	  
cancer cells into a migratory cell state by blocking MET may be a more rational approach for 243	  
preventing metastasis, by inhibiting the ability of these cells to colonize the secondary organ 244	  
(Figure 1). However, one limitation of this approach could be the requirement for life-long therapy. 245	  
 246	  
The fibroblast growth factor receptor isoform FGFR2IIIc is a critical determinant of the epithelial 247	  
phenotype in T24-TSU bladder carcinoma cells, and targeting of FGFR2IIIc may be a strategy to 248	  
inhibit MET [55]. By varying the site of cancer cell inoculation, Chaffer et al. have developed 249	  
mouse models of metastasis that mimic specific stages of the metastatic cascade [55]. Using these 250	  
models the authors confirm that mesenchymal-type cancer cells are associated with a higher 251	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metastatic burden when orthotopically injected [55], and thus required to undergo all of the stages 252	  
of the metastatic cascade including invasion, intravasation, circulation and metastatic colonization. 253	  
However, when cells are injected by intracardiac or intratibial injection, which bypasses the 254	  
invasion/intravasation steps, cells with a more epithelial phenotype and high expression of 255	  
FGFR2IIIc are associated with a greater incidence of micrometastatic deposits [55]. In this vein, 256	  
silencing of FGFR2IIIc reduces mortality in an intracardiac inoculation model [55]. These findings 257	  
highlight the importance of developing sensitive diagnostic tools to accurately characterize the stage 258	  
of the metastatic cascade at diagnosis, in parallel with the development of stage-specific 259	  
pharmacological agents for anti-metastatic therapy. 260	  
 261	  
Although many studies reinforce the relationships between EMT and/or the mesenchymal 262	  
phenotype and cancer stem cell activities, examples of stem/pluripotency activity associated with 263	  
epithelial features are now accumulating (reviewed in [56]). Elegant studies by Tsai et al. [57] and 264	  
Ocana et al. [58] have recently demonstrated a need for MET for metastatic capacity [36], building 265	  
on observations of malignant competency in epithelial rather than mesenchymal variants of both 266	  
T24-TSU bladder carcinoma cells and PC3 prostate carcinoma cells [59].  Ocana and colleagues 267	  
were able to dissociate stem-like characteristics from the mesenchymal state by manipulating the 268	  
Prrx1 transcription factor [58], and Sarrio et al. could associate specific stem-like activities in 269	  
epithelial subcompartments of normal, basal breast cell lines [60]. Most recently, Liu and 270	  
colleagues [61] demonstrated that breast cancer stem cells isolated from breast cancers exist in 271	  
distinct mesenchymal-like and epithelial-like states, defined by the CD44HIGH/CD24LOW and 272	  
aldehyde dehydrogenase markers respectively. The plasticity that allows these cells to transition 273	  
between EMT- and MET-like states endows them with the capacity for tissue invasion, 274	  
dissemination, and growth at metastatic sites. Together, these data begin to suggest that the 275	  
plasticity ascribed to cancer stem cells may actually arise from their ability to retain both epithelial 276	  
and mesenchymal characteristics at the same time. In other words, cancer stem cells reside in the 277	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partial EMT state described above. In this case, it makes sense that ‘stemness’ is lost in cells that 278	  
are locked either in the epithelial or mesenchymal state. This offers further opportunity for 279	  
targeting, by either i) locking cells in the dormant mesenchymal state, which has been shown to be 280	  
poorly malignant if there is insufficient plasticity to reacquire proliferative potential [59]; or ii) by 281	  
blocking the early, epithelially-dependent steps towards proliferative competence. Only 282	  
comprehensive experimentation can determine where the best approaches lie.	  283	  
 284	  
Concluding remarks 285	  
There are a variety of potential pharmacological approaches to exploit the EMT process to prevent 286	  
or target cancer metastasis. Approaches include inhibiting the induction of EMT, targeting the 287	  
invasive mesenchymal cell type and locking the cells in dormancy by preventing MET. Each of 288	  
these approaches has potential strengths and weaknesses in the context of the development of 289	  
effective clinical agents. In particular, agents that inhibit the mesenchymal state could accelerate 290	  
epithelialization of disseminated deposits and thus drive the formation of metastases; whereas 291	  
agents that target MET could promote mesenchymalization and therapy resistance in pre-metastatic 292	  
cancers. It is therefore necessary to foster research into each of these approaches for targeting EMT 293	  
in cancer, with the aim to build an arsenal of stage-specific anti-EMT agents for more personalized 294	  
cancer treatment. Rigorous testing of such agents in combination with existing therapies is required 295	  
in models representing the full spectrum of the metastatic process and emulating the usual course of 296	  
therapy and relapse. However, it should be noted that EMT is not a prerequisite for the metastasis of 297	  
all cancer types, as evidenced by the development of secondary metastases in neu- and PyMT- 298	  
initiated tumors in the absence of any mesenchymal-like transformation [7]. This suggests that, 299	  
although EMT appears to have a central role in cancer metastasis, other mechanisms are also 300	  
involved. In this context, a better understanding of the type of cancers where EMT is important and 301	  
the identification of appropriate biomarkers may be a key step towards the clinical use of 302	  
pharmacological agents to target EMT in cancer therapy. 303	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Figure (i): Features of epithelial and mesenchymal cell types. 311	  
Molecular markers and phenotypic traits that are commonly used to distinguish epithelial and 312	  
mesenchymal cell types in in vitro, in vivo and clinical studies of EMT. 313	  
 314	  
Figure 1: Strategies for inhibiting the EMT pathway in cancer. 315	  
Strategies to inhibit the EMT pathway in cancer include i) inhibiting signals from the tumor 316	  
microenvironment that induce EMT; ii) blocking signal transduction pathways that convey EMT 317	  
initiating signals; iii) targeting the mesenchymal cell state; and iv) blocking colonization via MET. 318	  
Ca2+, calcium; EGF, epidermal growth factor; EMT, epithelial-mesenchymal transition; FGFR, 319	  
fibroblast growth factor receptor; MET, mesenchymal-epithelial transition; MMP, matrix 320	  
metalloproteinase; STAT, signal transducer and activator of transcription; TGF, transforming 321	  
growth factor. 322	  
  323	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Table 1: Examples of receptors, enzymes and transporter proteins that have been linked to EMT in 324	  
cancer and are possible targets for inhibiting EMT-associated metastasis. 325	  
 326	  
Potential 
targeta 
Examples of 
pharmacological inhibitorsb Cancer type 
Consequences of inhibition/silencing 
Ref(s). 
EMT marker(s) Migration/Invasion 
Receptors (~44% of drug targets) – includes GPCRs, ligand-gated ion channels, receptor tyrosine kinases & nuclear receptors  
Axl BGB324*  SGI7079 
Breast 
↔↓↓  ↓↓  [48, 49, 62, 63] 
Colon  ↓↓  [64] 
Liver ↓  ↓  [65] 
Neuroblastoma ↔ ↓  [66] 
Oral ↓  ↓  [67] 
Pancreatic ↓  ↓    [68] 
Prostate ↓  ↓  [69] 
c-Met SU11274* 
Breast ↓↓  ↓↓  [70, 71] 
Gastric ↓  ↓  [72] 
CXCR4 
AMD3100 (Plerixafor)* 
TN14003*  
AMD3465 
Breast ↓   [73] 
Glioma ↓  ↓  [74] 
Head and neck  ↓  [75] 
Liver  ↓  [76, 77] 
Pancreatic ↓  ↓  [78] 
Prostate ↓  ↓  [79] 
EGFR 
AG1478* 
OSI774 (Erlotinib)*  
ZD1839 (Gefitinib)*  
Biliary ↓↓  ↓  [80, 81] 
Breast ↓  ↓  [27, 82] 
Cervical ↓   [83, 84] 
Endometrial  ↓  ↓  [85] 
Head and neck ↓  ↓  [86, 87] 
Lung ↓   [88] 
Ovarian ↓↓  ↓↓  [89-91] 
Pancreatic ↓  ↓  [92] 
Prostate  ↓  [93] 
ETAR 
ABT627 (Atrasentan)* 
BQ123* 
ZD4054 (Zibotentan)* 
Ovarian ↓↓  ↓↓  [94-96] 
IGF1R 
AG1024* 
I-OMe-AG538*  
Picropodophyllin* 
Breast ↓  ↓  [97] 
Lung ↓   [98] 
α7-nAChR 
α-Bungarotoxin* 
Methyllcaconitine* 
MG624 
Breast  ↓  [99] 
Colon ↓↓  ↓↓  [100, 101] 
Gastric ↓  ↓↓  [102] 
Lung  ↓  [99] 
Notch-1 
 Breast ↓   [103] 
Liver ↓  ↓  [104] 
Lung ↓  ↓  [105-107] 
Notch-2 
 Lung ↓   [108] 
Pancreatic ↓  ↓  [109, 110] 
Notch-3  Breast ↓   [111] 
Notch-4 
 Breast ↓  ↓  [112] 
Lung ↓   [108] 
Pancreatic ↔   [109] 
P2X5  Breast ↓   [113] 
SMO 
Cyclopamine*  
IPI926 (Saridegib)* 
NVPLDE225 (Erismodegib)* 
Gastric ↓ ↓ [114] 
Head and neck ↑  ↑  [86] 
Pancreatic ↓  ↓  [78, 115] 
Prostate ↓  ↓  [116] 
TGFβRI 
LY36497* 
LY2157299 
SD208 
Liver ↓↔ ↓↓  [77] 
uPAR  
Breast ↓  ↓  [25] 
Medulloblastoma ↓  ↓  [117] 
Enzymes (~29% of drug targets) – includes hydrolases, transferases, oxidoreductases & ligases  
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COX2 
Apricoxib* 
Celecoxib* 
NS398*  
Bladder ↓  ↓  [118] 
Breast ↓  ↓  [119] 
Colon ↓  ↓  [100, 120, 
121] 
Gastric  ↓↓  [122] 
Liver ↓↓  ↓  [123, 124] 
Pancreatic ↓   [125] 
Erk2 TCS ERK 11e (VX-11e) Prostate ↓   [126] 
FAK 
FAK inhibitor 14 (1,2,4,5-
Benzenetetraamine 
tetrahydrochloride)* 
GSK2256098  
PF-573228  
Ovarian ↓  ↓  [127] 
FUT4  Breast ↓  ↓  [128] 
ILK 
KP392* 
QLT0267* 
T315* 
 
Bladder ↓  ↓  [129, 130] 
Breast ↓↓  ↓  [131, 132] 
Ovarian ↓  ↓  [94] 
Prostate ↓↓  ↓  [132, 133] 
Tongue ↓  ↓  [134] 
MMP3 MMP3 Inhibitor IV* Prostate ↓  ↓  [135] 
MMP9 
MMP9 Inhibitor I 
 
Head and neck ↓  ↓  [87] 
Skin ↓  ↓  [136] 
PIMT  Breast ↓  ↓  [137] 
SHP2 SPI112Me Breast ↓  ↓  [138] 
TG2 KCC-009 
Ovarian ↓  ↓  [139] 
Skin ↓  ↓  [140] 
Transporter proteins (~15% of drug targets) – includes voltage gated ion channels, solute carriers & other ion channels  
LIV-1 
 Breast ↑   [141, 142] 
Cervical ↓  ↓  [143] 
Liver ↓   [144] 
Pancreatic ↓  ↓  [145] 
Prostate ↓  ↓  [93, 146] 
KCNN4 TRAM34* Colon ↓↓  ↓↓  [147] 
TRPM7c Waixenicin A Breast ↓   [29] 
Red indicates gene silencing approach  
Blue indicates pharmacological approach  
Arrows indicate either an inhibitory (↓), promoting (↑) or neutral (↔) effect on either EMT markers or migration/invasion. 
a Examples of proposed EMT targets, where the specific protein target has been identified and assessed for its role in EMT in cancer cells 
b Up to three specific and/or non-specific pharmacological inhibitors listed for each target  
c Ion channel and kinase (EC 2) 
* Indicates a pharmacological inhibitor that was used in at least one EMT study listed in reference column  
COX2, cyclooxygenase 2; CXCR4, chemokine (C-X-C motif) receptor 4; EGFR, epidermal growth factor receptor; Erk2, extracellular signal-regulated kinase 
2; ETAR, endothelin receptor type A; FAK, focal adhesion kinase; FUT4, fucosyltransferase 4; GPCR, G-protein coupled receptor; IGF1R, insulin-like growth 
factor type 1 receptor; ILK, integrin linked kinase; KCNN4, potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; 
MMP3, matrix metalloproteinase-3; MMP9, matrix metalloproteinase-9; α7-nAChR, α7 nicotinic acetylcholine receptor; P2X5, purinergic receptor X5; PIMT, 
protein L-isoaspartyl O-methyltransferase; SHP2, Src homology phosphotyrosine phosphatase 2; SMO, smoothened; TG2, tissue transglutaminase; 
TGFβR1, transforming growth factor β receptor type 1; TRPM7, transient receptor potential cation channel, subfamily M, member 7; uPAR, urokinase 
plasminogen activator receptor. 
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Box 1: Epithelial and mesenchymal cell profiles. 329	  
To escape the confines of the primary tumor and establish distant metastases tumor cells must 330	  
acquire a more invasive phenotype, invade the extracellular matrix, survive transit in the circulation 331	  
and colonize the secondary organ(s). Epithelial-mesenchymal transition (EMT) is a process 332	  
implicated in the early stages of the metastatic cascade, and involves the cellular conversion to a 333	  
more invasive (mesenchymal) cell type. Once cancer cells have reached the secondary organ they 334	  
are thought to undergo the reverse process, mesenchymal-epithelial transition (MET) for metastatic 335	  
colonization. In addition to promoting cancer metastasis via the loss of cell-cell adhesions and gain 336	  
of protease-dependent invasion, EMT is also thought to generate cancer stem cells and contribute to 337	  
the acquired resistance of some cancers to chemo- and radiotherapy. Some of the molecular and 338	  
phenotypic characteristics of epithelial- and mesenchymal- type cancer cells are shown in Figure (i). 339	  
  340	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